Efficacy and Safety of PCSK9 Monoclonal Antibodies in Patients With Diabetes
Author:
Publisher
Elsevier BV
Subject
Pharmacology (medical),Pharmacology
Reference122 articles.
1. Hyperlipidaemia 3 Ed: Diagnosis and Management;Durrington,2007
2. Hypercholesterolaemia—practical information for non-specialists;Soran;Archives of medical science,2018
3. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel;Ference;European heart journal,2017
4. The importance of considering LDL cholesterol response as well as cardiovascular risk in deciding who can benefit from statin therapy;Soran;Current opinion in lipidology,2014
5. Cholesterol, not just cardiovascular risk, is important in deciding who should receive statin treatment;Soran;European heart journal,2015
Cited by 7 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Safety profile of proprotein convertase subtilisin/kexin type 9 inhibitors alirocumab and evolocumab: an updated meta-analysis and meta-regression;Current Medical Research and Opinion;2024-06-11
2. Effects of PCSK9 on thrombosis and haemostasis in a variety of metabolic states: Lipids and beyond (Review);International Journal of Molecular Medicine;2024-05-10
3. Treatment of dyslipidemia in metabolic syndrome;Vnitřní lékařství;2024-04-10
4. Impact of PCSK9 inhibitors in glycaemic control and new-onset diabetes;Cardiovascular Diabetology;2024-01-03
5. Lipid-lowering in diabetes: An update;Atherosclerosis;2023-10
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3